Clinical Trials Logo

Stage III Ureter Cancer AJCC v7 clinical trials

View clinical trials related to Stage III Ureter Cancer AJCC v7.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03244384 Active, not recruiting - Clinical trials for Locally Advanced Urothelial Carcinoma

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

AMBASSADOR
Start date: November 3, 2017
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Monoclonal antibodies recognizing and blocking checkpoint molecules can enhance the patient's immune response and therefore help fight cancer. Pembrolizumab is one of the monoclonal antibodies that block the PD-1 axis and can interfere with the ability of tumor cells to grow.

NCT ID: NCT02812420 Active, not recruiting - Hydronephrosis Clinical Trials

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Start date: March 7, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects of durvalumab and tremelimumab in treating patients with muscle-invasive, high-risk urothelial cancer that cannot be treated with cisplatin-based therapy before surgery. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.